South Downs Health NHS Trust, Chailey Heritage Clinical Services, East Sussex, UK.
Dev Med Child Neurol. 2011 Jan;53(1):34-9. doi: 10.1111/j.1469-8749.2010.03786.x. Epub 2010 Sep 24.
The aims of this study were to identify all people with Lesch-Nyhan disease (LND) born in the UK between 1988 and 2008, and to obtain a clinical profile including age at diagnosis, genetic background, family history, neurological signs, and medications.
Potential participants were contacted through the British Paediatric Neurology Surveillance Unit. Questionnaires were sent to each child's paediatric neurologist or primary consultant. Two purine laboratories provided metabolic information.
Twenty-three live males with LND in the 0- to 20-year age band and eight live males over the age of 20 years were identified. Thirty-one live people with LND were identified in the UK in 2008, giving a prevalence of 1 in 2 million people. Over the 20 years of study, there was a mean incidence rate of 0.18 per 100 000 live births, range 0 to 0.5.
To our knowledge, this study is the first to provide details of the prevalence and incidence of LND in the UK. The data highlight that clinical profiles, at the time of diagnosis, and management of the disease are variable. There is the need for ongoing monitoring of allopurinol dosage and metabolic screening.
本研究旨在确定英国在 1988 年至 2008 年间出生的所有莱施-尼汉病(LND)患者,并获得包括诊断时年龄、遗传背景、家族史、神经体征和药物治疗等在内的临床特征。
通过英国儿科神经病学监测单位联系潜在参与者。向每个患儿的儿科神经科医生或主要顾问发送了调查问卷。两家嘌呤实验室提供了代谢信息。
在 0-20 岁年龄组中确定了 23 名存活的男性 LND 患者,20 岁以上的存活男性患者有 8 名。在 2008 年,英国共发现 31 名 LND 存活患者,患病率为每 200 万人中有 1 人。在 20 年的研究中,平均发病率为每 10 万活产儿 0.18 例,范围为 0 至 0.5。
据我们所知,这项研究首次提供了英国 LND 的患病率和发病率的详细信息。这些数据突出表明,疾病的临床表现、诊断时的治疗和管理存在差异。需要持续监测别嘌呤醇的剂量和代谢筛查。